Dr Alysha Elliott Aparicio

Research Fellow

Institute for Molecular Bioscience
+61 7 334 62745


Doctor Alysha Elliott is a Research Fellow at the Centre for Superbug Solutions in the Institute for Molecular Bioscience at The University of Queensland. Alysha began her research career in 2007 and has since been dedicated to multi-disciplinary drug discovery with a specific passion for anti-infective targeted research. Alysha is highly experienced in infectious disease microbiology, structural biology of peptides, and molecular biology. Developing new antibiotics to treat drug resistant pathogens and investigating mechanisms of resistance in bacteria are Alysha’s core research activities.

Dr Elliott is the Program Coordinator for Microbiology and Screening for the Community for Open Antimicrobial Drug Discovery (CO-ADD), a global antibiotic discovery initiative that has screened >300,000 unique compounds via high throughput screening technologies for antimicrobial activity from over 270 research groups from 47 countries. Alysha’s antimicrobial drug development research has been funded by NHMRC, CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), the Wellcome Trust and the Queensland Government (Advance Queensland). She has published more than sixty research articles and is active in collaborating with industry and public private partnerships for translational outcomes.

Dr Elliott’s current core research focus is on alternative therapies to treat extensively drug resistant Gram-negative bacterial infections, in particular the use of potentiators (inactive or inefficient compounds when used alone as an antimicrobial) to restore activity of traditional antibiotics that are no longer effective due to the development of antimicrobial resistance.

Research Interests

  • Bacterial pathogens
  • Antimicrobial Resistance
  • Alternative therapies to treat bacterial infections

Research Impacts

Dr Elliott's research focuses on the development of new antimicrobial therapies to combat multi-drug and extensively drug resistant bacteria. New therapies are critical to the treatment of bacterial infections as drug resistance increases at alarming rates, with an estimate of 10 million deaths per year by 2050 if nothing substantial is done, and very few candidates are left in the pharmaceutical development pipeline. Going hand in hand with development of new therapies is the investigation of resistance mechanisms in bacteria, where understanding how bacteria develop resistance to antibiotics over time provides guidance on how to better design new compounds or treatment strategies to fight drug resistant infections.


  • Bachelor of Applied Science (Biochemistry), Queensland University of Technology
  • Doctor of Philosophy, The University of Queensland
  • Bachelor of Science (Hons), The University of Queensland


View all Publications


View all Supervision


Featured Publications

Journal Article

Conference Publication

Other Outputs

  • Gallardo-Goday, Alejandra, Cooper, Matthew, Blaskovich, Mark, Hansford, Karl and Elliott, Alysha (2019). Peptide antibiotics. WO2019084628.

  • Elliott, Alysha Gai (2013). A new class of daisy seed peptides. PhD Thesis, The Institute for Molecular Bioscience, The University of Queensland.

Grants (Administered at UQ)

PhD and MPhil Supervision

Note for students: Dr Alysha Elliott Aparicio is not currently available to take on new students.

Current Supervision